SCHEMBL3014674

SCHEMBL3014674

O=S(=O)(c1ccc(Cl)cc1Cl)C1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.42
CTSS P25774 6/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
AR P10275 1/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTR2A P28223 1/20 0.36
PTGER1 P34995 1/20 0.36
HRH4 Q9H3N8 2/20 0.36
DNM1L O00429 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006012 0.94 MAPT (0.39) TRPV4CTSSGAARAB9ASMN1; SMN2
SCHEMBL3022234 0.92 RECQL (0.39) TRPV4CTSSGAARAB9ASMN1; SMN2
SCHEMBL3015043 0.92 GAA (0.40) TRPV4CTSSGAARAB9ASMN1; SMN2
SCHEMBL3007871 0.91 CTSS (0.37) TRPV4CTSSGAARAB9ASMN1; SMN2
SCHEMBL2998446 0.91 GAA (0.36) CTSSGAARAB9ASMN1; SMN2AR
SCHEMBL3019472 0.91 CTSS (0.36) CTSSRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3002748 0.91 CTSS (0.48) CTSSRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3013562 0.91 GAA (0.36) CTSSGAARAB9ASMN1; SMN2AR
SCHEMBL3009754 0.90 CTSS (0.45) CTSSRAB9ASMN1; SMN2NPC1HTR2A
SCHEMBL3002782 0.90 CTSS (0.37) TRPV4CTSSGAARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885CTSS 106/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.